2023
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations
Ślusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.Peer-Reviewed Original ResearchConceptsHigher PSA levelsNonmetastatic prostate cancerLocal therapyRadical prostatectomyPSA levelsOverall survivalProstate cancerGood long-term oncological outcomesHigher prostate-specific antigen levelLong-term oncological outcomesProstate-specific antigen levelProstate-specific antigen concentrationCS estimatesInitial local therapyRadical local therapyUnderwent radical prostatectomyEnd Results (SEER) databaseKaplan-Meier methodLong-term outcomesIndependent prognostic valueISUP grade groupCox proportional hazardsImproved CSSPrimary radiotherapyOncological outcomes
2019
Associations of rurality and disease outcomes in urologic malignancies.
Abello A, Casilla-Lennon M, Kenney P, Leapman M. Associations of rurality and disease outcomes in urologic malignancies. Journal Of Clinical Oncology 2019, 37: 661-661. DOI: 10.1200/jco.2019.37.7_suppl.661.Peer-Reviewed Original ResearchCancer-specific deathAssociation of ruralityUrologic malignanciesKidney cancerPoor cancer-specific survivalCox proportional hazards modelRural statusRural countiesCancer-specific survivalEnd Results (SEER) databaseProportional hazards modelPopulation-level dataDefinitive treatmentRural patientsGenitourinary malignanciesTestis cancerUrologic cancersWorse outcomesCancer incidenceDisease PDisease outcomeUrological cancersMultivariable regressionWhite raceOutcome data